Actively Recruiting
Phase 2 Study of Two Vipoglanstat Doses to Treat Moderate to Severe Endometriosis Pain in Women Aged 18 to 44
Led by Gesynta Pharma AB · Updated on 2026-04-17
190
Participants Needed
41
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of vipoglanstat on non-menstrual pelvic pain NMPP related to endometriosis in women aged 18 to 44 years. This Phase 2 trial aims to assess how well vipoglanstat works and its safety in treating moderate to severe pain caused by endometriosis. The study is sponsored by Gesynta Pharma AB and is designed as a randomized, double-blind, placebo-controlled trial.
CONDITIONS
Brief Title
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
Research Team
C
CMO VP Clinical Development
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
